National Academy of Sciences | 150 Year Anniversary

Questions? Call 800-624-6242

About | Ordering | New

Menu menu

| Items in cart [0]

The National Academies Press

PAPERBACK
price:$43.00
add to cart

Rights & Permissions

topleft topright

Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health (2006)
Board on Science, Technology, and Economic Policy (STEP)

Citation Manager

. "4 Trends in the Patenting and Licensing of Genomic and Protein Inventions and Their Impact on Biomedical Research." Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health. Washington, DC: The National Academies Press, 2006.

Please select a format:

BibTeX EndNote RefMan
Page
124
bottomleft bottomright
  E-mail
Share on facebook Facebook
Share on delicious Delicious
Share on stumbleupon Stumble
Share on twitter Twitter
More Sharing ServicesMore

The following HTML text is provided to enhance online readability. Many aspects of typography translate only awkwardly to HTML. Please use the page image as the authoritative form to ensure accuracy.

Reaping the Benefits of Genomic and Proteomic Research: Intellectual Property Rights, Innovation, and Public Health

TABLE 4-3 Reasons for Not Pursuing Projects, by Research Goal and Pathway

 

Random Sample

Research Goal

Pathways

Drug Discovery

Basic Research

Other

CTLA4

EGF

NF-kB

No Funding

62

86

60

58

63

54

82

Too Busy

60

55

60

59

53

58

48

Not Feasible

46

41

46

47

33

55

53

Not Scientifically Important

40

24

41

45

40

36

50

Not Interesting

35

24

36

33

20

30

29

Too Much Competition

29

21

32

21

27

29

29

Little Social Benefit

15

21

14

15

13

5

22

Unreasonable Terms

10

21

9

6

7

9

19

Not Help w/Promotion/Job

10

21

7

15

0

13

5

Too Many Patents

3

3

2

3

0

4

0

New Firm Unlikely

3

3

2

3

0

4

0

Little Commercial Potential

2

3

2

3

0

4

0

Little Income Potential

1

3

1

3

0

4

0

Not Patentable

1

3

1

3

0

4

0

Respondents

274

28

213

33

16

24

22

 

SOURCE: Walsh et al., 2005.
Page
124